Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid (Q39293482)

10 September 2017

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid (English)

1 reference

primary biliary cholangitis

10 September 2017

0 references

author name string

Akira Honda

1

1 reference

10 September 2017

Tadashi Ikegami

2

1 reference

10 September 2017

Makoto Nakamuta

3

1 reference

10 September 2017

Teruo Miyazaki

4

1 reference

10 September 2017

Junichi Iwamoto

5

1 reference

10 September 2017

Takeshi Hirayama

6

1 reference

10 September 2017

Yoshifumi Saito

7

1 reference

10 September 2017

Hajime Takikawa

8

1 reference

10 September 2017

Michio Imawari

9

1 reference

10 September 2017

Yasushi Matsuzaki

10

1 reference

10 September 2017

language of work or name

English

0 references

publication date

5 April 2013

1 reference

10 September 2017

1 reference

10 September 2017

57

1 reference

10 September 2017

5

1 reference

10 September 2017

1931-1941

1 reference

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

10 September 2017

1 reference

The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis

21 January 2018

1 reference

Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone

21 January 2018

1 reference

Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.

21 January 2018

1 reference

Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis.

21 January 2018

1 reference

The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study

21 January 2018

1 reference

Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice

21 January 2018

1 reference

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

Highly sensitive and specific analysis of sterol profiles in biological samples by HPLC-ESI-MS/MS.

21 January 2018

1 reference

High sensitive analysis of rat serum bile acids by liquid chromatography/electrospray ionization tandem mass spectrometry

21 January 2018

1 reference

Disrupted coordinate regulation of farnesoid X receptor target genes in a patient with cerebrotendinous xanthomatosis

21 January 2018

1 reference

Significance of plasma 7alpha-hydroxy-4-cholesten-3-one and 27-hydroxycholesterol concentrations as markers for hepatic bile acid synthesis in cholesterol-fed rabbits

21 January 2018

1 reference

Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.

21 January 2018

1 reference

A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

21 January 2018

1 reference

CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes

21 January 2018

1 reference

Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism

21 January 2018

1 reference

Transcriptional regulation of the PXR gene: identification and characterization of a functional peroxisome proliferator-activated receptor alpha binding site within the proximal promoter of PXR.

21 January 2018

1 reference

The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression

21 January 2018

1 reference

Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression

21 January 2018

1 reference

Benefit of farnesoid X receptor inhibition in obstructive cholestasis

21 January 2018

1 reference

Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice

21 January 2018

1 reference

Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter.

21 January 2018

1 reference

4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans

21 January 2018

1 reference

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide

21 January 2018

1 reference

Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor

21 January 2018

1 reference

The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity

21 January 2018

1 reference

An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids.

21 January 2018

1 reference

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

21 January 2018

1 reference

Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor

21 January 2018

1 reference

Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle

21 January 2018

1 reference

Effects of long-term rifampicin administration in primary biliary cirrhosis

21 January 2018

1 reference

Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.

21 January 2018

1 reference

PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide

21 January 2018

1 reference

Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review

21 January 2018

1 reference

Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients

21 January 2018

1 reference

Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment.

21 January 2018

1 reference

Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population

21 January 2018

1 reference

The PXR is a drug target for chronic inflammatory liver disease

21 January 2018

1 reference

A Retrospective on Nuclear Receptor Regulation of Inflammation: Lessons from GR and PPARs

21 January 2018

1 reference

Primary biliary cirrhosis

21 January 2018

1 reference

7 January 2021

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

7 January 2021

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

1 reference

7 January 2021

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial

1 reference

7 January 2021

Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

1 reference

7 January 2021

Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis

1 reference

7 January 2021

Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.26018

1 reference

release_e2i6bayaoncujninfqmns3waji

10 September 2017

0 references

1 reference